ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

RemeGen, Pfizer and Jiangsu HengRui Medicine side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

RemeGen×Pfizer×Jiangsu HengRui Medicine×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

RemeGenPfizerJiangsu HengRui Medicine
studies on the registry834,0731,066
open to participants now42147307
phase 3 studies under way1899105
reach primary completion within a year593130
programswith a study of their own in two years1091+9 named only156+1 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseRemeGenPfizerJiangsu HengRui Medicine
Phase 100%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

Jiangsu HengRui Medicine: 53 of its 156 programs at phase 1

  1. Rifampinphase 1
  2. HRS-5817phase 1
  3. HRS-2189phase 1
  4. SHR-2017phase 1
  5. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1

and 48 more — sign in to see them all

34%
Phase 2

RemeGen: 5 of its 10 programs at phase 2

  1. Anti-c-Met/MMAE ADC RC108phase 2
  2. ABBV-1480phase 2
  3. RC278phase 2
  4. RC288phase 2
  5. telisotuzumab adizutecanphase 2
50%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%

Jiangsu HengRui Medicine: 50 of its 156 programs at phase 2

  1. SHR-1139phase 2
  2. SHR-1826phase 2
  3. SHR-2173phase 2
  4. SHR-9839phase 2
  5. HRS-4508phase 2

and 45 more — sign in to see them all

32%
Phase 3

RemeGen: 5 of its 10 programs at phase 3

  1. disitamab vedotinphase 3
  2. RC148phase 3
  3. telitaciceptphase 3
  4. RC28-E proteinphase 3
  5. tislelizumabphase 3
50%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

Jiangsu HengRui Medicine: 51 of its 156 programs at phase 3

  1. adebrelimabphase 3
  2. trastuzumab rezetecanphase 3
  3. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3
  4. ribupatidephase 3
  5. notiretatug rezetecanphase 3

and 46 more — sign in to see them all

33%
Approved, new studies00%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Jiangsu HengRui Medicine: 2 of its 156 programs at approved, new studies

  1. vunakizumabapproved, new study
  2. remimazolam tosylateapproved, new study
1%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
RemeGen3 readouts · 3 phase 3·

RemeGen, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. disitamab vedotinphase 3 · Dec 0 · NCT06221748
  2. telitaciceptphase 3 · Dec 31 · NCT07249632
····

RemeGen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. RC148phase 3 · May 12 · NCT07462143
·····
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
Jiangsu HengRui Medicine75 readouts · 11 phase 3

Jiangsu HengRui Medicine, Nov ’26: 2 programs whose next study reaches primary completion

  1. HRS-1780phase 3 · Nov 0 · NCT07470983
  2. SHR-1681phase 2 · Nov 0 · NCT06737731

Jiangsu HengRui Medicine, Dec ’26: 32 programs whose next study reaches primary completion, 4 in phase 3

  1. adebrelimabphase 3 · Dec 0 · NCT05482568
  2. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1 · Dec 0 · NCT06443489
  3. BP102phase 3 · Dec 0 · NCT06915142
  4. drotokibartphase 3 · Dec 0 · NCT07688772
  5. HRS-1596phase 1 · Dec 0 · NCT07841860

and 27 more — sign in to see them all

Jiangsu HengRui Medicine, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. RSS0393phase 3 · Jan 0 · NCT07543224
  2. SHR 3201phase 1 · Jan 0 · NCT07889349
  3. SHR-4375phase 2 · Jan 0 · NCT07298772
  4. HRS-5817phase 1 · Jan 30 · NCT07238647

Jiangsu HengRui Medicine, Feb ’27: 8 programs whose next study reaches primary completion

  1. FH-006phase 3 · Feb 0 · NCT07136142
  2. HRS-5346phase 2 · Feb 0 · NCT07767513
  3. HRS-8080phase 3 · Feb 0 · NCT07876596
  4. KRAS G12D Inhibitor HRS-4642phase 3 · Feb 0 · NCT07906691
  5. RSS0343phase 2 · Feb 0 · NCT07940829

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Mar ’27: 8 programs whose next study reaches primary completion, 3 in phase 3

  1. Anti-CD79b Antibody-drug Conjugate SHR-A1912phase 3 · Mar 0 · NCT06929624
  2. HRS-1893phase 3 · Mar 0 · NCT07269717
  3. HRS-4139phase 1 · Mar 0 · NCT07802964
  4. HRS-4729phase 2 · Mar 0 · NCT07690826
  5. ivarmacitinibphase 3 · Mar 0 · NCT07251595

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Apr ’27: 6 programs whose next study reaches primary completion

  1. HRS-4029phase 2 · Apr 0 · NCT07739160
  2. HRS-5632phase 2 · Apr 0 · NCT07185776
  3. SHR-1703phase 3 · Apr 0 · NCT07701239
  4. SHR-2173phase 2 · Apr 0 · NCT07354932
  5. SHR-4602phase 2 · Apr 0 · NCT06704828

and 1 more — sign in to see them all

Jiangsu HengRui Medicine, May ’27: 1 program whose next study reaches primary completion

  1. SHR-4712phase 1 · May 0 · NCT06993116

Jiangsu HengRui Medicine, Jun ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-7249phase 2 · Jun 0 · NCT07308392
  2. HRS8179phase 3 · Jun 0 · NCT06732648
  3. SHR-1819phase 3 · Jun 0 · NCT07321951
  4. SHR-1918phase 3 · Jun 0 · NCT07308392
  5. SHR-9803phase 2 · Jun 0 · NCT06906731

Jiangsu HengRui Medicine, Jul ’27: 5 programs whose next study reaches primary completion

  1. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3 · Jul 0 · NCT07682272
  2. ruzinuradphase 3 · Jul 0 · NCT07362355
  3. aumolertinibphase 3 · Jul 30 · NCT05503888
  4. retlirafusp alfaphase 3 · Jul 30 · NCT05503888
  5. SHR-9539phase 1 · Jul 31 · NCT06484777
·

Jiangsu HengRui Medicine, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-4508phase 2 · Sep 0 · NCT07003321
  2. garetatug rezetecanphase 3 · Sep 20 · NCT06649292

Jiangsu HengRui Medicine, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-5965phase 3 · Oct 0 · NCT07014826
  2. SHR-2524phase 1 · Oct 0 · NCT07478302
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

RemeGen

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

Jiangsu HengRui Medicine

New programs 11

Reached a new phase 4

  • SHR-3167phase 3 · Oct 28 · Diabetes Mellitus, Type 2
  • HRS-6209phase 3 · Oct 14 · Breast Neoplasms
  • HRS-7172phase 2 · Sep 2 · Pancreatic Neoplasms
  • FH-006phase 3 · Aug 25 · Lung Neoplasms

Study stopped 0

None

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 44 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionRemeGenPfizerJiangsu HengRui Medicine
Carcinoma, Non-Small-Cell Lungall three · compare here

RemeGen in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. disitamab vedotinphase 3
  2. RC148phase 3
  3. tislelizumabphase 3
  4. Anti-c-Met/MMAE ADC RC108phase 2
  5. ABBV-1480phase 2

and 1 more — sign in to see them all

Their studies: RemeGen’s studies of Carcinoma, Non-Small-Cell Lung in search

Pfizer in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 3 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

RemeGen in Breast Neoplasms: 2 programs

  1. disitamab vedotinphase 3
  2. RC148phase 3

Their studies: RemeGen’s studies of Breast Neoplasms in search

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Jiangsu HengRui Medicine in Breast Neoplasms: 9 programs

  1. adebrelimabphase 3
  2. trastuzumab rezetecanphase 3
  3. HRS-8080phase 3
  4. ruzaltatug rezetecanphase 3
  5. HRS-6209phase 3

and 4 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Breast Neoplasms in search

Colorectal Neoplasmsall three · compare here

RemeGen in Colorectal Neoplasms: 2 programs

  1. RC148phase 3
  2. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Colorectal Neoplasms in search

Pfizer in Colorectal Neoplasms: 4 programs

  1. tivunatamigphase 3
  2. tusamitamab sonditecanphase 1
  3. tucatinibapproved, new study
  4. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Colorectal Neoplasms in search

Jiangsu HengRui Medicine in Colorectal Neoplasms: 4 programs

  1. trastuzumab rezetecanphase 3
  2. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3
  3. BP102phase 3
  4. Trastuzumabphase 3

Their studies: Jiangsu HengRui Medicine’s studies of Colorectal Neoplasms in search

Neoplasmsall three · compare here

RemeGen in Neoplasms: 1 program

  1. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Neoplasms in search

Pfizer in Neoplasms: 2 programs

  1. polfurmetinibphase 1
  2. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Jiangsu HengRui Medicine in Neoplasms: 6 programs

  1. adebrelimabphase 3
  2. zeprumetostatphase 3
  3. efserakefusp alfaphase 3
  4. Trastuzumabphase 3
  5. risvutatug rezetecanphase 2

and 1 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Neoplasms in search

Stomach Neoplasmsall three · compare here

RemeGen in Stomach Neoplasms: 2 programs

  1. disitamab vedotinphase 3
  2. tislelizumabphase 3

Their studies: RemeGen’s studies of Stomach Neoplasms in search

Pfizer in Stomach Neoplasms: 2 programs

  1. tivunatamigphase 3
  2. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Stomach Neoplasms in search

Jiangsu HengRui Medicine in Stomach Neoplasms: 5 programs

  1. trastuzumab rezetecanphase 3
  2. retlirafusp alfaphase 3
  3. zeprumetostatphase 3
  4. garetatug rezetecanphase 3
  5. Trastuzumabphase 3

Their studies: Jiangsu HengRui Medicine’s studies of Stomach Neoplasms in search

Non-Muscle Invasive Bladder Neoplasmsall three · compare here

RemeGen in Non-Muscle Invasive Bladder Neoplasms: 1 program

  1. disitamab vedotinphase 3

Their studies: RemeGen’s studies of Non-Muscle Invasive Bladder Neoplasms in search

Jiangsu HengRui Medicine in Non-Muscle Invasive Bladder Neoplasms: 2 programs

  1. efserakefusp alfaphase 3
  2. SHR-2005phase 1

Their studies: Jiangsu HengRui Medicine’s studies of Non-Muscle Invasive Bladder Neoplasms in search

Lupus Erythematosus, Systemicall three · compare here

RemeGen in Lupus Erythematosus, Systemic: 1 program

  1. telitaciceptphase 3

Their studies: RemeGen’s studies of Lupus Erythematosus, Systemic in search

Pfizer in Lupus Erythematosus, Systemic: 2 programs

  1. dazukibartphase 3
  2. PF-08154225phase 2

Their studies: Pfizer’s studies of Lupus Erythematosus, Systemic in search

Jiangsu HengRui Medicine in Lupus Erythematosus, Systemic: 1 program

  1. SHR-2173phase 2

Their studies: Jiangsu HengRui Medicine’s studies of Lupus Erythematosus, Systemic in search

Squamous Cell Carcinoma of Head and Neckall three · compare here

RemeGen in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Squamous Cell Carcinoma of Head and Neck in search

Pfizer in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpha V Beta 8 Antagonist PF-06940434phase 1

Their studies: Pfizer’s studies of Squamous Cell Carcinoma of Head and Neck in search

Jiangsu HengRui Medicine in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. notiretatug rezetecanphase 3
  2. SHR-9839phase 2

Their studies: Jiangsu HengRui Medicine’s studies of Squamous Cell Carcinoma of Head and Neck in search

Carcinoma, Transitional Cellall three · compare here

RemeGen in Carcinoma, Transitional Cell: 1 program

  1. disitamab vedotinphase 3

Their studies: RemeGen’s studies of Carcinoma, Transitional Cell in search

Pfizer in Carcinoma, Transitional Cell: 1 program

  1. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Carcinoma, Transitional Cell in search

Jiangsu HengRui Medicine in Carcinoma, Transitional Cell: 1 program

  1. notiretatug rezetecanphase 3

Their studies: Jiangsu HengRui Medicine’s studies of Carcinoma, Transitional Cell in search

Obesity2 of 3 · compare here–

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

Jiangsu HengRui Medicine in Obesity: 7 programs

  1. ribupatidephase 3
  2. Safiglipronphase 3
  3. HRS-4729phase 2
  4. HRS-5817phase 1
  5. HRS-1597phase 1

and 2 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Obesity in search

Dermatitis, Atopic2 of 3 · compare here–

Pfizer in Dermatitis, Atopic: 7 programs

  1. tilrekimigphase 3
  2. abrocitinibphase 3
  3. etrasimodphase 3
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Dermatitis, Atopic in search

Jiangsu HengRui Medicine in Dermatitis, Atopic: 6 programs

  1. ivarmacitinibphase 3
  2. drotokibartphase 3
  3. SHR-1905phase 3
  4. RSS0393phase 3
  5. SHR-1819phase 3

and 1 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Dermatitis, Atopic in search

Prostatic Neoplasms2 of 3 · compare here–

Pfizer in Prostatic Neoplasms: 1 program

  1. mevrometostatphase 3

Their studies: Pfizer’s studies of Prostatic Neoplasms in search

Jiangsu HengRui Medicine in Prostatic Neoplasms: 11 programs

  1. zeprumetostatphase 3
  2. rezvilutamidephase 3
  3. HRS-4357phase 3
  4. GnRH Antagonist SHR7280phase 3
  5. HRS-5041phase 2

and 6 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Prostatic Neoplasms in search

Show all 44

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: RemeGen 5 of 10 · Pfizer 67 of 91 · Jiangsu HengRui Medicine 67 of 156 programs (35 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9, Jiangsu HengRui Medicine: 1).